Key Contraceptives Market Players:
- Bayer AG (Germany)
- Organon & Co. (U.S.)
- CooperSurgical, Inc. (U.S.)
- Reckitt (UK)
- Pfizer Inc. (U.S.)
- Ansell Limited (Australia)
- Pregna International Ltd. (India)
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pregna International Ltd. is considered to be a leading manufacturer of intrauterine contraceptive devices in India which is offering copper IUDs, hormonal contraceptives, and tubal rings. The company states that its products have reached over 100 million women across 140 countries.
- Bayer AG is also a prominent player in this sector, which offers a range of hormonal contraceptive methods, including oral contraceptives, intrauterine systems, patches, vaginal rings, implants, and injectables. The firm is highly focused on providing several contraceptive options based on individual needs.
- Organon & Co. primarily focuses on women's health, and its portfolio covers fertility and contraception, maternal health, and vaginal health. Apart from this, the company operates across more than 140 markets globally.
- CooperSurgical, Inc. offers Paragard®, which is an intrauterine copper contraceptive. The company operates within the fertility and medical devices sectors and is headquartered in Trumbull, Connecticut, U.S.
- Reckitt manufactures and markets Durex®, which it describes as the world's No. 1 condom brand. Also, Durex has more than 90 years of experience, and it extensively focuses on condom innovation, intimate wellness, and sexual security.
Here is a list of key players operating in the global market:
The global contraceptives market includes leading manufacturers such as Bayer, Organon, CooperSurgical, and Reckitt, and they are maintaining strong positions through broad product portfolios and established geographic presence. Competition in this sector spans hormonal contraceptives, intrauterine devices, implants, and condoms, whereas differentiation is driven by product efficacy, safety, innovation, brand strength, and clinical evidence. In this context, Viatris in July 2026 received U.S. FDA approval for Gwyn Lo™, which is a once-weekly combined hormonal contraceptive patch, and it delivers norelgestromin 220 mcg/day and ethinyl estradiol 20 mcg/day. The company also mentioned that phase 3 results showed contraceptive efficacy and strong patch adhesion.
Corporate Landscape of the Market: